Journal issues > Issue 1, February 2022 > Highlights in acute myeloid leukaemia

Highlights in acute myeloid leukaemia

SUMMARY

Over the past few years, the exploration of the genomic and molecular landscape of acute myeloid leukaemia (AML), identification of mutations associated with the pathogenesis and understanding of the mechanisms of resistance to treatment has led to a significant shift in the treatment paradigms for patients with AML, resulting in improved clinical outcomes.¹ Nevertheless, there is a persistent high need to improve survival and quality of life for patients with AML, especially with our aging population. During the Belgian Hematology Society post- ASH 2021 meeting Dr. Spilleboudt, Jules Bordet Institute, Brussels, gave a comprehensive summary of the highlights in advancements of AML treatment ranging from first line options, treatment in relapsed/refractory (R/R) patients, maintenance, and data on the burden of care in elderly patients.

(BELG J HEMATOL 2022;13(1):48-54)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top